Bayramgil, A.; Yücel, M.H.; Turkoglu, E.; Guren, A.K.; Kemik, F.; Ulufer, B.; Çakan Demirel, B.; Yildiz, A.; Sacli, O.; Ercin, E.;
et al. Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR. J. Clin. Med. 2026, 15, 2217.
https://doi.org/10.3390/jcm15062217
AMA Style
Bayramgil A, Yücel MH, Turkoglu E, Guren AK, Kemik F, Ulufer B, Çakan Demirel B, Yildiz A, Sacli O, Ercin E,
et al. Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR. Journal of Clinical Medicine. 2026; 15(6):2217.
https://doi.org/10.3390/jcm15062217
Chicago/Turabian Style
Bayramgil, Ayberk, Mehmet Haluk Yücel, Ezgi Turkoglu, Ali Kaan Guren, Fatih Kemik, Bedirhan Ulufer, Burçin Çakan Demirel, Anil Yildiz, Omer Sacli, Eda Ercin,
and et al. 2026. "Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR" Journal of Clinical Medicine 15, no. 6: 2217.
https://doi.org/10.3390/jcm15062217
APA Style
Bayramgil, A., Yücel, M. H., Turkoglu, E., Guren, A. K., Kemik, F., Ulufer, B., Çakan Demirel, B., Yildiz, A., Sacli, O., Ercin, E., Demircan, N. C., Kinikoglu, O., Lacin, S., Bilici, A., Altintas, Y. E., & Ozcelik, M.
(2026). Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR. Journal of Clinical Medicine, 15(6), 2217.
https://doi.org/10.3390/jcm15062217
